FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to ophthalmology, and is intended for preventing or treating age-related macular degeneration. For preventing or treating of age-related macular degeneration, including wet age macular dystrophy and dry age macular dystrophy, as medicinal agent S-allyl-L-cysteine is used, or its pharmaceutically acceptable salt or solvate or hydrate.
EFFECT: use of invention enables more effective prevention or treatment of age-related macular degeneration.
5 cl, 2 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION CONTAINING NORBIXIN FOR PROTECTING CELLS OF RETINAL PIGMENT EPITHELIUM | 2016 |
|
RU2715889C2 |
| CHEMICAL COMPOUNDS ACTING ON EYES, AND THEIR USE IN TREATING EYE DISEASES | 2020 |
|
RU2830634C1 |
| NEUTRAL ENDOPEPTIDASE (NEP) AND SOLUBLE HUMAN ENDOPEPTIDASE (SHE) INHIBITORS FOR PREVENTION AND TREATMENT OF EYE DISEASES | 2019 |
|
RU2758771C1 |
| USE OF THE COMPOUND OF FORMULA I, A PHARMACEUTICAL COMPOSITION, A MEDICINAL AGENT | 2016 |
|
RU2730854C2 |
| DERIVATIVES OF N-UREA-SUBSTITUTED AMINOACIDS AS MODULATORS OF FORMYL-PEPTIDE RECEPTOR | 2014 |
|
RU2696581C2 |
| USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING INFLAMMATORY EYE DISEASES | 2014 |
|
RU2663911C2 |
| AGENT FOR PREVENTION AND TREATMENT OF OCULAR DISEASES, SUCH AS RETINAL DISEASES, GLAUCOMA AND CATARACT | 2017 |
|
RU2660366C1 |
| METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION | 2009 |
|
RU2668371C2 |
| USE OF FORMYL PEPTIDE RECEPTOR 2 AGONISTS FOR TREATING INFLAMMATORY EYE DISEASES | 2014 |
|
RU2768730C2 |
| ARYL UREA DERIVATIVES AS N-FORMILEPEPTIDE-1 RECEPTOR (FPRL-1) MODULATORS | 2012 |
|
RU2627271C2 |
